Arikayce liposomal
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Amikacin
- Made by
- Insmed Netherlands B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
BulgariaNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Insmed Netherlands B.V. |
|---|---|
| Active substance | Amikacin |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J01GB06 · Antibiotics, antivirals and antifungals taken into the body |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2020-10-27 |
| Last updated by the regulator | 2026-08-05 |
| EMA product number | EMEA/H/C/005264 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).